CN117083275B - 心脏肌节抑制剂 - Google Patents

心脏肌节抑制剂

Info

Publication number
CN117083275B
CN117083275B CN202280017911.8A CN202280017911A CN117083275B CN 117083275 B CN117083275 B CN 117083275B CN 202280017911 A CN202280017911 A CN 202280017911A CN 117083275 B CN117083275 B CN 117083275B
Authority
CN
China
Prior art keywords
compound
disease
pharmaceutically acceptable
compounds
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202280017911.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN117083275A (zh
Inventor
B·P·摩根
C·庄
L·W·阿什克拉夫特
J·霍
A·加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of CN117083275A publication Critical patent/CN117083275A/zh
Application granted granted Critical
Publication of CN117083275B publication Critical patent/CN117083275B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
CN202280017911.8A 2021-03-04 2022-03-03 心脏肌节抑制剂 Active CN117083275B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163156853P 2021-03-04 2021-03-04
US63/156,853 2021-03-04
PCT/US2022/018725 WO2022187501A1 (en) 2021-03-04 2022-03-03 Cardiac sarcomere inhibitors

Publications (2)

Publication Number Publication Date
CN117083275A CN117083275A (zh) 2023-11-17
CN117083275B true CN117083275B (zh) 2026-08-04

Family

ID=80937093

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280017911.8A Active CN117083275B (zh) 2021-03-04 2022-03-03 心脏肌节抑制剂

Country Status (14)

Country Link
US (2) US11919909B2 (cg-RX-API-DMAC7.html)
EP (1) EP4301760A1 (cg-RX-API-DMAC7.html)
JP (1) JP7850737B2 (cg-RX-API-DMAC7.html)
KR (1) KR20240015622A (cg-RX-API-DMAC7.html)
CN (1) CN117083275B (cg-RX-API-DMAC7.html)
AR (1) AR125026A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022229390A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023017461A2 (cg-RX-API-DMAC7.html)
CA (1) CA3209557A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023002616A1 (cg-RX-API-DMAC7.html)
IL (1) IL305628A (cg-RX-API-DMAC7.html)
MX (1) MX2023010125A (cg-RX-API-DMAC7.html)
TW (1) TW202302594A (cg-RX-API-DMAC7.html)
WO (1) WO2022187501A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
MA53491A (fr) 2018-08-31 2021-09-15 Cytokinetics Inc Inhibiteurs de sarcomes cardiaques
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
CN119998292A (zh) * 2022-09-02 2025-05-13 赛特凯恩蒂克公司 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047447A1 (en) * 2018-08-31 2020-03-05 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US5919785A (en) 1996-04-03 1999-07-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US20030158186A1 (en) 2001-12-21 2003-08-21 Fady Malik Compositions and methods for treating heart failure
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
WO2004086865A1 (en) 2003-03-27 2004-10-14 Cytokinetics, Inc. Compounds, compositions and methods
US20070155713A1 (en) 2003-04-21 2007-07-05 Rena Nishizawa Nitrogen-containing heterocyclic compounds and use thereof
US7507735B2 (en) 2004-06-17 2009-03-24 Cytokinetics, Inc. Compounds, compositions and methods
MX2007006230A (es) 2004-11-30 2007-07-25 Amgen Inc Quinolinas y analogos de quinazolinas y su uso como medicamentos para tratar cancer.
US20060173183A1 (en) 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
TW200718692A (en) 2005-04-22 2007-05-16 Wyeth Corp Dihydrobenzofuran derivatives and uses thereof
WO2007078815A2 (en) 2005-12-16 2007-07-12 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
US20090192168A1 (en) 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
ES2459468T3 (es) 2009-05-15 2014-05-09 Novartis Ag Arilpiridinas como inhibidores de aldosterona sintasa
US8592426B2 (en) 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
TWI576347B (zh) 2012-01-20 2017-04-01 艾克泰聯製藥有限公司 作為p2x受體拮抗劑之雜環醯胺衍生物
SMT202000071T1 (it) 2013-06-21 2020-03-13 Myokardia Inc Composti di pirimidinadione contro le condizioni cardiache
US9199945B2 (en) 2013-06-21 2015-12-01 MyoKardia, Inc. Cycloalkyl-substituted pyrimidinedione compounds
US9663516B2 (en) 2014-12-18 2017-05-30 MyoKardia, Inc. Bicyclic-pyrimidinedione compounds
CN104539229A (zh) 2014-12-26 2015-04-22 金海新源电气江苏有限公司 一种太阳能光伏支架
SG11201705928XA (en) 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
CN108430997B (zh) 2015-12-17 2021-06-04 先正达参股股份有限公司 杀微生物的噁二唑衍生物
US20190364899A1 (en) 2015-12-18 2019-12-05 Syngenta Participations Ag Microbiocidal oxadiazole derivatives
CA3022432A1 (en) 2016-04-29 2017-11-02 Board Of Regents, The University Of Texas System Sigma receptor binders
EP3475275B1 (en) 2016-06-23 2024-04-10 Merck Sharp & Dohme LLC 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors
SI3519416T1 (sl) 2016-09-27 2021-08-31 Merck Sharp & Dohme Corp. Derivati kromana, izokromana in dihidroizobenzofurana kot mGluR2-negativni alosterični modulatorji, sestavki in njihova uporaba
WO2018089433A1 (en) 2016-11-08 2018-05-17 Navitor Pharmaceuticals, Inc. PHENYL mTORC INHIBITORS AND USES THEREOF
US20200000822A1 (en) 2017-02-23 2020-01-02 Board Of Regents, The University Of Texas System Methods of treatment for cancer, sterol homeostasis, and neurological diseases
IL322175A (en) 2017-08-04 2025-09-01 Myokardia Inc Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds
SG11202006296YA (en) 2018-01-19 2020-08-28 Cytokinetics Inc Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
EP3814343B1 (en) 2018-06-26 2023-01-11 Cytokinetics, Inc. Cardiac sarcomere inhibitors
JP7438148B2 (ja) 2018-06-26 2024-02-26 サイトキネティックス, インコーポレイテッド 心臓サルコメア阻害剤
US10981905B2 (en) 2018-08-31 2021-04-20 Xenon Pharmaceuticals Inc. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
IL325304A (en) 2018-10-29 2026-02-01 Myokardia Inc 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione
LT3999180T (lt) 2019-07-17 2024-08-26 Cytokinetics, Inc. (r)-n-(5-(5-etil-1,2,4-oksadiazol-3-il)-2,3-dihidro-1h-inden-1-il)-1-metil-1h-pirazol-4-karboksamido polimorfai
WO2021011808A1 (en) 2019-07-17 2021-01-21 Cytokinetics, Inc. Cardiac sarcomere inhibitor oral formulations
CA3157629A1 (en) 2019-11-10 2021-05-14 MyoKardia, Inc. Methods of treatment with myosin modulator
KR20230079053A (ko) 2020-08-28 2023-06-05 미요카디아, 인크. 미오신 조절제를 이용한 치료 방법
CN114456163B (zh) 2020-11-09 2023-08-11 江苏恒瑞医药股份有限公司 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114516843B (zh) 2020-11-19 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
EP4249474A4 (en) 2020-11-20 2024-04-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Triazine dione derivative, preparation method therefor and application thereof in medicine
CN116507621B (zh) 2020-11-24 2025-10-17 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539229B (zh) 2020-11-24 2024-10-22 江苏恒瑞医药股份有限公司 嘧啶二酮类衍生物、其制备方法及其在医药上的应用
CN114539257B (zh) 2020-11-24 2023-08-11 江苏恒瑞医药股份有限公司 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用
AR125588A1 (es) 2021-03-04 2023-08-02 Lilly Co Eli Compuestos inhibidores de fgfr3
KR20240015622A (ko) 2021-03-04 2024-02-05 싸이토키네틱스, 인코포레이티드 심장 근절 억제제
CN119998292A (zh) 2022-09-02 2025-05-13 赛特凯恩蒂克公司 5-(3,4-二氟苄基)-8-((1r,4r)-4-甲基环己基)-6,9-二氧代基-2,5,8-三氮杂螺[3.5]壬烷-2-甲醛的结晶形式

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020047447A1 (en) * 2018-08-31 2020-03-05 Cytokinetics, Inc. Cardiac sarcomere inhibitors

Also Published As

Publication number Publication date
BR112023017461A2 (pt) 2023-09-26
AU2022229390A1 (en) 2023-09-21
WO2022187501A1 (en) 2022-09-09
TW202302594A (zh) 2023-01-16
JP2024508526A (ja) 2024-02-27
MX2023010125A (es) 2023-09-11
KR20240015622A (ko) 2024-02-05
US12286437B2 (en) 2025-04-29
EP4301760A1 (en) 2024-01-10
CL2023002616A1 (es) 2024-02-02
US20240309011A1 (en) 2024-09-19
CL2024001620A1 (es) 2024-11-04
AR125026A1 (es) 2023-05-31
CN117083275A (zh) 2023-11-17
JP7850737B2 (ja) 2026-04-23
CA3209557A1 (en) 2022-09-09
IL305628A (en) 2023-11-01
US11919909B2 (en) 2024-03-05
US20220306642A1 (en) 2022-09-29

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40102197

Country of ref document: HK

GR01 Patent grant